[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-or-metastatic-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-or-metastatic-breast-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100453691","phase-1-a-study-of-and019-in-women-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-100453691",false,"NCT05187832","A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer","A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer","Key Inclusion Criteria:\n\n1. Postmenopausal women defined as NCCN guideline at the time of informed consent.\n2. Histological or cytological confirmation of advanced or metastatic ER+\u002FHER2- breast cancer women who failed standard therapy or for which no standard therapy exists.\n3. Prior therapy:\n\n   1. No more than 1 line of chemotherapy for advanced breast cancer\n   2. Recurrence or progression on at least one line of endocrine therapy in the advanced or metastatic disease setting and derived a clinical benefit from the endocrine therapy: Recurred or progressed while being treated with adjuvant endocrine therapy for a duration of at least 24 months, or progressed under endocrine therapy for more than 6 months in the advanced or metastatic setting\n4. ECOG score 0-1.\n5. Minimum life expectancy of a least 3 months as determined by the Investigator.\n6. Evaluable disease per RECIST 1.1; for patients consent to tissue biopsy, disease suitable for tumor biopsy.\n7. Sufficient bone marrow reserve and organ function.\n\nKey Exclusion Criteria:\n\n1. Previous treatment with any SERDs.\n2. Patient any central nervous system metastasis.\n3. Prior antitumor therapies:\n\n   1. Received chemotherapies within 3 weeks before the first dose.\n   2. Received systemic radiotherapy within 3 weeks before the first dose, or local radiotherapy within 7 days before the first dose\n   3. Received other anti-tumor therapy such as endocrine therapy, immunotherapy, and target therapy within 3 weeks or 5 half-lives of the drug before the first dose of the study drug\n   4. For bone metastasis, bisphosphonates and local remission therapy are allowed (7 days washout for local radiation therapy).\n4. Patient who has participated in any other clinical trials for drugs or treatments within 5 half-lives for a prior investigational drug or 2 weeks from use of an investigational device prior to the first dose of study drug.\n5. Patient who had major surgery or significant trauma within 4 weeks prior to the first dose of study drug (excluding needle biopsy), or has scheduled surgery during the study period.\n6. Patient with serous unhealable wounds\u002Fulcers\u002Ffractures within 4 weeks prior to the first dose of study drug.\n7. Patient with adverse reactions to previous anti-tumor treatments who have not yet recovered to grade ≤1 according to CTCAE v5.0. (except for toxicities without safety risks as judged by Investigator, such as alopecia, grade 2 peripheral neuropathy etc.)\n8. Patient who has used strong inhibitors or strong inducers of CYP3A, or grapefruit or grapefruit juice within 4 weeks prior to the first dose of study drug.\n9. Patient unable to be administered oral medications or any condition that seriously affect digestion in the gastrointestinal tract at the judgement of the Investigator.\n10. Patient with active infection within 1 week prior to the first dose of study drug, and currently need systemic anti-infective treatment.\n11. Patient has a known history of the following: HIV infection without effective antiretroviral therapy (ART) or acceptable immune function, or syphilis infection, or HBsAg positive HBV or needs prophylaxis therapy or suppressive antiviral therapy before dosing, or has an HCV infection that hasn't completed curative antiviral treatment or with unacceptable viral load.\n12. Patient has active cardiac disease or a history cardiac dysfunction.\n13. Patient with third spacing that cannot be controlled clinically and is not suitable for the study by the Investigator's judgment.\n14. Patient with known history of drug abuse.\n15. Patient with mental disorder that, in the opinion of the Investigator, could lead to poor compliance with required study procedures.\n16. Patient that cannot tolerate venous blood sampling.\n17. Known to have other malignancy within the past 5 years, and is progressing or requires active treatment (except skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ who have received potentially radical treatment)","FEMALE","18 Years",{"count":19,"type":20},61,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \\[HER2\\]-negative) breast cancer.",[26],"Advanced or Metastatic Breast Cancer","RECRUITING","2026-02-25",{"date":30,"type":31},"2026-02-27","ACTUAL",{"date":33,"type":31},"2022-10-05",{"date":35,"type":20},"2026-11",{"name":37,"class":38},"Kind Pharmaceuticals LLC","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100531548","phase-2-evaluating-the-addition-of-elacestrant-oral-serd-to-olaparib-parp-inhibitor-in-patients-with-advancedmetastatic-hrher2--breast-cancer-100531548","NCT06201234","Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced\u002FMetastatic HR+\u002FHER2- Breast Cancer","Phase II Study Evaluating the Addition of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), to Standard-of-care Olaparib in Patients With Hormone Receptor (HR)-Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer With gBRCA1\u002F2 Mutations","ELEMENT","Inclusion Criteria:\n\nPatients will be eligible for study participation only if they comply with the following criteria:\n\n1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for scheduled visit, the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.\n2. Female or male patients.\n3. Age at study entry of at least 18 years.\n4. Locally advanced or metastatic breast cancer that is HR-positive (ER and\u002For PgR ≥ 10% of stained cells at IHC) and HER2-negative (IHC 0 or 1+, or 2+ and ISH negative according to ASCO\u002FCAP guidelines).\n5. Patients with deleterious or suspected deleterious gBRCA1\u002F2 mutation detected upon local testing.\n6. Willingness and ability to provide archived formalin fixed paraffin embedded tissue (FFPE) block or a partial block from archived tumor or metastasis.\n7. Indication for standard-of-care PARP inhibitor therapy and planned treatment with olaparib.\n8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.\n9. Resolution of all acute toxic effects of prior anti-cancer therapy including endocrine therapy or surgical procedures to NCI CTCAE version 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).\n10. Life-expectancy \\> 6 months.\n11. For female patients: patients of childbearing potential (defined as not post-menopausal and not permanently sterile \\[latter defined as having undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\\]) require a negative serum or urinary pregnancy test within 72 hours before starting treatment in this study (in this case, patients need to use highly effective non-hormonal contraceptive methods as specified in the protocol).\n\nFor male patients: during the intervention period and for at least 120 days after the last dose of elacestrant, patients should refrain from heterosexual intercourse or use a condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak), and they should refrain from donating sperm.\n\nExclusion Criteria:\n\nPatients will be ineligible for study participation if they fulfill any of the following criteria:\n\n1. Known hypersensitivity reaction to one of the compounds, excipients, or substances used in this protocol.\n2. Active or newly diagnosed CNS metastases, including leptomeningeal carcinomatosis, carcinomatous meningitis, or radiographic signs of CNS hemorrhage. Note: Patients with stable brain metastases are allowed. Radiotherapeutic treatment must be completed 1 week before planned day 1 of study therapy.\n3. Presence of symptomatic metastatic visceral disease that are at risk of life-threatening complications in the short term, including but not confined to massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or fulminant liver involvement.\n4. Inadequate organ function prior to enrolment including:\n\n   * Hemoglobin \\\u003C 9 g\u002FdL (\\\u003C 5.6 mmol\u002FL)\n   * Absolute neutrophil count (ANC) \\\u003C 1500\u002Fmm³ (\\\u003C 1.5 x 109\u002FL)\n   * Platelets \\\u003C 100,000\u002Fmm³ (\\\u003C 100 x 109\u002FL)\n   * Alanine aminotransferase (ALT\u002FSGPT) and\u002For aspartate aminotransferase (AST\u002FSGOT) \\> 3 x upper normal limits (ULN). If the patient has liver metastases, ALT and AST should not be ≥ 5 x ULN.\n   * Alkaline phosphatase (ALP) \\> 2.5 x ULN\n   * Total serum bilirubin \\> 1.5 x ULN (exception: patients with Gilbert's syndrome permitted up to ≤ 3 x ULN)\n   * Serum creatinine \\> 1.5 x ULN or estimated creatinine clearance \\\u003C 50 mL\u002Fmin as calculated using the standard method for the institution.\n5. Existing contraindication against the use of the elacestrant or olaparib.\n6. Prior treatment with PARP inhibitors.\n7. Female patients: pregnancy or lactation at the time of randomization or intention to become pregnant during the study and for a predefined period after the end of treatment (as described in protocol).\n\n   Male patients: intention to get a child during the study and for a predefined period after the end of treatment (as described in protocol).\n\n   According to the treatment received during the study, required contraception timelines for female and male patients are described in the study protocol.\n8. Any of the following within 6 months prior to enrolment: myocardial infarction, severe\u002Funstable angina, ongoing grade ≥ 2 cardiac dysrhythmias, prolonged QT corrected by Fridericia's formula (QTcF) grade ≥ 2, uncontrolled atrial fibrillation of any grade, coronary\u002Fperipheral artery bypass graft, heart failure of New York Heart Association (NYHA) Class II or greater, or cerebrovascular accident including transient ischemic attack.\n9. Uncontrolled hypertension at the time of screening (systolic BP \\> 140 mmHg or diastolic BP \\> 90 mmHg that has not been adequately treated or controlled).\n10. Active and current anticoagulation for treatment purposes of thrombotic events occurring \\\u003C 6 months before enrolment is not allowed (prophylactic anticoagulation, however, is acceptable). Treatment with an anticoagulant for a thrombotic event occurring \\> 6 months before enrolment, or for an otherwise stable and allowed medical condition (e.g., well controlled atrial fibrillation) is acceptable, provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 28 days prior to the first dose of study drug.\n11. Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications such as: uncontrolled nausea or vomiting (i.e., CTCAE ≥ grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction\u002Fmotility disorder, malabsorption syndrome, or prior gastric bypass.\n12. History of endometrial intraepithelial neoplasia in patients who have not undergone a hysterectomy.\n13. Malignant disease other than breast cancer, active or being disease-free for less than 5 years (except carcinoma in situ of the cervix, DCIS, and non-melanomatous skin cancer adequately treated).\n14. Uncontrolled significant active infections including HBV, HCV, and\u002For HIV. Patients with a positive hepatitis B surface antigen result or a positive hepatitis C antibody test result at screening or within 3 months before first dose of study treatment are excluded, except for the following:\n\n    * Participants with positive anti-HBs antibody titer and confirmatory negative hepatitis B DNA polymerase chain reaction.\n    * Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if they have both completed curative therapy and have a hepatitis C viral load \\\u003C quantifiable limit.\n15. Any severe, acute, uncontrolled, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational or non-investigational products administration, or may interfere with the interpretation of study results, and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. Moreover, patients who, by virtue of an order issued by judicial or administrative authorities, are committed to an institution or those who cannot take part in clinical trials are excluded from this study.\n16. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent.\n17. Unable or unwilling to avoid medications, supplements (e.g., St. John's wort), or foods (e.g., grapefruit, pomegranate, pomelos, star fruit, Seville oranges and their juices) that are moderate\u002Fstrong inhibitors or inducers of CYP3A4 activity. Participation will be allowed if the medication, supplements, or foods are discontinued for at least 14 days prior to study entry and for the duration of the study.\n18. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.\n19. Receipt of live attenuated vaccination within 30 days prior to study entry. COVID-19 vaccines that do not contain live viruses are allowed (at least one week prior to study entry).","ALL",{"count":50,"type":20},176,[52],"PHASE2","Trial design:\n\nPhase II, prospective, multi-center, randomized, open label, parallel group study in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1\u002F2 mutation, with 2:1 randomization into Arm A (olaparib + elacestrant) or arm B (olaparib). Treatment in either arm will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study.\n\nTrial population:\n\nPatients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1\u002F2 mutation, with an indication for standard-of-care PARP inhibitor therapy and planned treatment with olaparib, an ECOG performance status of 0-2 and life expectancy of \\> 6 months, with normal bone marrow and kidney functions and no active or newly diagnosed central nervous system (CNS) metastases or symptomatic metastatic visceral disease at risk of life-threatening complications.\n\nInterventions:\n\nPatients randomized to Arm A will receive 600 mg olaparib daily and 400 mg elacestrant daily, while patients randomized to Arm B will receive 600 mg olaparib daily. Blood tests (hematology, biochemistry) will be performed at the beginning of every cycle, and imaging for tumor assessment (chest and abdominopelvic imaging) as well as QoL assessments will be performed every three months and in case of suspicion of progression\u002Fend of study.",[55,26,56,57],"Hormone Receptor Positive HER-2 Negative Breast Cancer","BRCA1 Mutation","BRCA2 Mutation",[59,60,61,62,63],"Elacestrant","Olaparib","Breast cancer","Metastases","Palliative therapy","2025-11-24",{"date":66,"type":31},"2025-12-01",{"date":68,"type":31},"2024-12-13",{"date":70,"type":20},"2028-12-31",{"name":72,"class":73},"GBG Forschungs GmbH","OTHER",36,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":39},"100587926","the-efficacy-of-oral-cryotherapy-in-preventing-trop2-adc-induced-oral-mucositis-in-patients-with-advanced-breast-cancer-100587926","NCT06934733","The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer","The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer: A Randomized, Controlled, Multicenter Clinical Study","Inclusion Criteria:\n\n1. Participants voluntarily enrolled in the study, signed the informed consent form, and demonstrated good compliance.\n2. Age ≥ 18 years at the time of informed consent signing.\n3. Patients with locally advanced or recurrent\u002Fmetastatic breast cancer receiving TROP2-ADC treatment for the first time.\n4. ECOG PS: 0-2 points;\n5. The expected survival time was more than 3 months;\n6. Adequate organ and bone marrow function, with no transfusions or treatments with recombinant human thrombopoietin or colony-stimulating factors within 1 week before the first dose, is defined as follows:\n\n   1. Blood routine: Neutrophil count (NEUT#) ≥ 1.5×109\u002FL; Platelet (PLT) ≥ 75×109\u002FL; Hemoglobin ≥ 90g\u002FL\n   2. Liver function: AST and ALT ≤ 3 × ULN; for patients with liver metastasis, AST and ALT ≤ 5 × ULN.\n   3. Renal function: Creatinine ≤ 1.5 × ULN or Ccr ≥ 60 ml\u002Fmin (Cockcroft-Gault formula provided).\n   4. Cardiac function: LVEF ≥ 50% by ECHO or MUGA scan.\n7. Patients with a negative pregnancy test and reproductive potential must agree to use effective non-hormonal contraception during treatment and for at least 3 months after the last dose of the investigational drug.\n8. Voluntary participants who sign informed consent, demonstrate good compliance, and agree to follow-up.\n\nExclusion Criteria:\n\n1. Prior TROP2-targeted treatment was administered.\n2. Patients with active oral mucositis or oral ulcers were excluded.\n3. Patients with serious concomitant diseases, as judged by researchers, that threaten safety or impede study completion, including uncontrolled hypertension, severe diabetes, and active infections, were excluded.\n4. Other conditions where the investigator determines the patient is unsuitable for study participation.",{"count":83,"type":20},124,[85],"NA","The incidence of oral mucositis associated with TROP2-ADC therapy in patients with advanced breast cancer is notably high. Identifying effective preventive and therapeutic strategies is essential for enhancing patient quality of life and optimizing treatment outcomes. Oral cryotherapy has been demonstrated to be efficacious in mitigating oral mucositis induced by radiotherapy and chemotherapy. Consequently, this study seeks to investigate the potential preventive efficacy of oral cryotherapy on TROP2-ADC-induced oral mucositis in patients with advanced breast cancer",[26],"NOT_YET_RECRUITING","2025-04-11",{"date":91,"type":31},"2025-04-18",{"date":93,"type":20},"2025-05",{"date":95,"type":20},"2027-05",{"name":97,"class":98},"Henan Cancer Hospital","OTHER_GOV"]